| JNJ Stock | | | ARS 14,025 75.00 0.54% |
Chairman
Mr. Alex Gorsky is Chairman of the Board, Chief Executive Officer of Directors of the Company. He was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing, and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson Johnson in 2004 to join Novartis Pharmaceuticals Corporationrationration, where he served as head of the companys pharmaceutical business in North America. Mr. Gorsky returned to Johnson Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky also serves on the boards of the Travis Manion Foundation, the Congressional Medal of Honor Foundation, the National Academy Foundation, and the Wharton Board of Overseers. He is also a member of the Board of Directors of the Business Roundtable and serves as the Chairman of its Corporationrationrate Governance Committee. since 2012.
| Age | 63 |
| Tenure | 13 years |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset
(ROA) of
0.0881 % which means that it generated a profit of $0.0881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.2414 %, meaning that it generated $0.2414 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.
Johnson Johnson Co has accumulated 29.98
B in total debt with debt to equity ratio
(D/E) of 51.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Johnson Johnson has a current ratio of 1.41, which is within standard range for the sector. Debt can assist Johnson Johnson until it has trouble settling it off, either with new capital or with free cash flow. So, Johnson Johnson's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Johnson Johnson sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Johnson to invest in growth at high rates of return. When we think about Johnson Johnson's use of debt, we should always consider it together with cash and equity.
Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. JOHNSON JOHNSON operates under Drug Manufacturers - Major classification in Argentina and is traded on Buenos-Aires Stock Exchange. It employs 135100 people. Johnson Johnson Co (JNJ) is traded on Buenos Aires Exchange in Argentina and employs 35 people.
Management Performance
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dirk Brinckman, Chief Officer | |
| Robert Decker, Controller Officer | |
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | |
| Jessica Moore, VP Relations | |
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | |
| Joseph CPA, Ex CFO | |
| James Swanson, Ex Officer | |
| Elizabeth Forminard, Exec Counsel | |
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | |
| Peter Fasolo, Vice President - Global Human Resources | |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Johnson Stock
Johnson Johnson financial ratios help investors to determine whether Johnson Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Johnson with respect to the benefits of owning Johnson Johnson security.